RNS Number : 5324C Venture Life Group PLC 02 September 2024 2 September 2024 VENTURE LIFE GROUP PLC ("Venture Life", "VLG" or the "Group") Director/PDMR Shareholding Futher to the announcement on 23 August 2023 of the exercise of options by Jerry Randall (Chief Executive Officer) and Gianluca Braguti (Chief Manufacturing Officer), the Company announces that both Jerry Randall and Gianluca Braguti sold ordinary shares of 0.3 pence each in the capital of the Company ("Ordinary Shares") in order to satisfy personal tax liabilities resulting from the exercise of the options (the "Share Sale"). Details of the Share Sale and the resultant beneficial interests' in the Company by both Jerry Randall and Gianluca Braguti are as follows: For further information, please contact: Venture Life Group PLC +44 (0) 1344 578004 Jerry Randall, Chief Executive Officer Daniel Wells, Chief Financial Officer Cavendish Capital Markets Limited (Nomad and Broker) +44 (0) 20 7720 0500 Stephen Keys / Camilla Hume (Corporate Finance) Michael Johnson (Sales) About Venture Life (www.venture-life.com) Venture Life is an international consumer self-care company focused on developing, manufacturing and commercialising products for the global self-care market. With operations in the UK, Italy, The Netherlands and Sweden, the Group's product portfolio includes some key products such as the UltraDEX and Dentyl oral care product ranges, the Balance Activ range in the area of women's intimate healthcare, the Lift and Glucogel product ranges for hypoglycaemia, Gelclair and Pomi-T for oncology support, Earol for ear wax removal, products for fungal infections and proctology, and dermo-cosmetics for addressing the signs of ageing. Its products are sold in over 90 countries worldwide. The products, which are typically recommended by pharmacists or healthcare practitioners, are available primarily through pharmacies and grocery multiples. In the UK and The Netherlands these are supplied direct by the company to retailers, elsewhere they are supplied by the Group's international distribution partners. Through its two Development & Manufacturing operations in Italy and Sweden, the Group also provides development and manufacturing services to companies in the medical devices and cosmetic sectors. The Company makes the following disclosures in accordance with article 19(3) of the Market Abuse Regulation: This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com. RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy. END DSHFIFVAAFIFIIS